Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology - TC Read more about Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology - TC
Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable - TC Read more about Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable - TC
Zai Lab to Host Conference Call to Discuss its License and Collaboration Agreement with Novocure for Tumor Treating Fields in Greater China - TC Read more about Zai Lab to Host Conference Call to Discuss its License and Collaboration Agreement with Novocure for Tumor Treating Fields in Greater China - TC
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China - TC Read more about Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China - TC
Zai Lab Announces Proposed Public Offering of American Depositary Shares - TC Read more about Zai Lab Announces Proposed Public Offering of American Depositary Shares - TC
Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018 - TC Read more about Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018 - TC
Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China - TC Read more about Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China - TC
Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis - TC Read more about Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis - TC
Zai Lab Announces Presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the IASLC 19th World Conference on Lung Cancer (WCLC) - TC Read more about Zai Lab Announces Presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the IASLC 19th World Conference on Lung Cancer (WCLC) - TC
Zai Lab’s ZL-2306 (niraparib) Completes Pharmacokinetics (PK) Study in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients - TC Read more about Zai Lab’s ZL-2306 (niraparib) Completes Pharmacokinetics (PK) Study in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients - TC